Author Archives: accsupport314

Annual Patient Information Day 2021 Success

The AMEND Annual Patient Information Day was held in person on Saturday 16th October, and welcomed people with a variety of different rare endocrine diseases and cancer, including ACC. It was a wonderful day of friendship and positivity, not least due to our amazing speakers, as evidenced by the superb feedback we have received.  We give you a round-up of the day and some of the links that you may need.  Please note that none of our sessions were recorded to protect patient privacy. “Absolutely super Continue reading →

New Scientist Insert Article on ACC

ACC Support recently worked with Health Awareness on the 2020 Rare Disease campaign. A printed publication was enclosed within every copy of the New Scientist and the content is available online at https://bit.ly/35OVrCe  . The campaign featured exclusive content from key thought leaders and, discussed the impact and sign and symptoms of Adrenocortical Cancer (ACC).    

EURINE-ACT Study Results Published in The Lancet

The results of the prospective EURINE-ACT study were published in The Lancet at 11:30pm on Thursday 23rd July, 2020.  The study, led by Professor Wiebke Arlt (IMSR Birmingham), involved 14 specialist centres in 11 countries, and 2169 participants (recruited between 2011 and 2016).  It has been successful in validating a new urine steroid metabolomics test for earlier diagnosis of ACC.  The study recommended changes in CT imaging practice and ultimately ‘a triple test strategy of tumour diameter, imaging characteristics, and urine steroid metabolomics’ to improve Continue reading →